Methods and compositions useful in generating non canonical CD8+ T cell responses

Patent metadata

Field	Value
Publication number	US-11091779-B2
Application number	US-202016738178-A
Country	US
Kind code	B2
Filing date	Jan 9, 2020
Priority date	Feb 10, 2015
Publication date	Aug 17, 2021
Grant date	Aug 17, 2021

Abstract

Methods of inducing a CD8+ T cell response to a heterologons antigen in which at least 10% of the CD8+ T cells are MHC-E restricted are disclosed. The method involves immunizing with a CMV vector that does not express UL128 and UL130 proteins. Also disclosed are recombinant CMV vectors comprising nucleic acids encoding a heterologous protein antigen, a UL40 protein, and a US28 protein but that do not express an active UL128 and UL130 protein. Also, disclosed are recombinant CMV vectors comprising nucleic acids encoding a heterologous protein antigen, but that do not express an active UL40 protein, UL128 protein, UL130 protein, and optionally a US28 protein. Also disclosed are recombinant CMV vectors comprising nucleic acids encoding a heterologous protein antigen, but that do not express an active US28 protein, UL128 protein, UL130 protein, and optionally a UL40 protein.

First claim

The invention claimed is:

1. A method of generating CD8 + T cells that recognize MHC-E-peptide complexes, the method comprising:
(1) administering to a first subject a recombinant cytomegalovirus (CMV) in an amount effective to generate a first set of CD8 + T cells that recognize MHC-E/peptide complexes, wherein the recombinant CMV vector comprises (a) a first nucleic acid sequence encoding at least one heterologous antigen; (b) a second nucleic acid sequence encoding at least one active UL40 protein, or an ortholog or homolog thereof; and (c) a third nucleic acid sequence encoding at least one active US28 protein, or an ortholog or homolog thereof; wherein the CMV vector does not express an active UL128 protein, or an ortholog thereof, and does not express an active UL130 protein, or an ortholog thereof;
(2) identifying a first CD8 + T cell receptor (TCR) from the first set of CD8 + T cells, wherein the first CD8 + TCR recognizes a MHC-E/heterologous antigen-derived peptide complex;
(3) isolating a second set of CD8 + T cells from the first subject or from a second subject; and
(4) transfecting the second set of CD8 + T cells with an expression vector, wherein the expression vector comprises a nucleic acid sequence encoding a second CD8 + TCR and a promoter operably linked to the nucleic acid sequence encoding the second CD8 + TCR, wherein the second CD8 + TCR comprises CDR3α and CDR3β of the first CD8 + TCR, thereby generating one or more transfected CD8 + T cells that recognize a MHC-E/heterologous antigen-derived peptide complex.

2. A transfected CD8+ T cell generated by the method of claim 1 which recognizes a MHC-E/heterologous antigen-derived peptide complex.

3. The CD8+ T cell of claim 2 , wherein the at least one heterologous antigen of the recombinant CMV vector comprises a pathogen-specific antigen.

4. The CD8+ T cell of claim 3 , wherein the pathogen-specific antigen is derived from a pathogen selected from the group consisting of: human immunodeficiency virus, simian immunodeficiency virus, herpes simplex virus, hepatitis B virus, hepatitis C virus, papillomavirus, Plasmodium parasites, and Mycobacterium tuberculosis.

5. A method of treating a pathogenic infection, the method comprising administering the CD8+ T cell of claim 3 to a subject.

6. A method of treating a pathogenic infection, the method comprising administering the CD8 + T cell of claim 4 to a subject.

7. The method of claim 6 , wherein the pathogen-specific antigen is derived from a human immunodeficiency virus.

8. The CD8 + T cell of claim 2 , wherein the at least one heterologous antigen of the CMV vector comprises a tumor antigen.

9. The CD8 + T cell of claim 8 , wherein the tumor antigen is related to a cancer selected from the group consisting of: acute myelogenous leukemia, chronic myelogenous leukemia, myelodysplastic syndrome, acute lymphoblastic leukemia, chronic lymphoblastic leukemia, non-Hodgkin's lymphoma, multiple myeloma, malignant melanoma, breast cancer, lung cancer, ovarian cancer, prostate cancer, pancreatic cancer, colon cancer, renal cell carcinoma (RCC), and germ cell tumors.

10. A method of treating cancer, the method comprising administering the CD8 + T cell of claim 8 to a subject.

11. The method of claim 1 , wherein the at least one heterologous antigen is derived from a pathogen selected from the group consisting of: human immunodeficiency virus, simian immunodeficiency virus, herpes simplex virus, hepatitis B virus, hepatitis C virus, papillomavirus, Plasmodium parasites, and Mycobacterium tuberculosis.

12. The method of claim 11 , wherein the at least one heterologous antigen is derived from human immunodeficiency virus.

13. The method of claim 1 , wherein the at least one heterologous antigen is derived from a tumor antigen.

14. The method of claim 1 , wherein the CMV vector does not express an active UL128 or UL130 protein, or orthologs thereof, due to the presence of one or more mutations in the nucleic acid sequence encoding UL128 or UL130, or orthologs thereof.

15. The method of claim 14 , wherein the one or more mutations in the nucleic acid sequence encoding UL128 or UL130, or orthologs thereof, are selected from the group consisting of: point mutations, frameshift mutations, truncation mutations, and deletion of all of the nucleic acid sequence encoding the protein.

16. The method of claim 1 , wherein the CMV vector further comprises at least one inactivating mutation in one or more viral genes encoding viral proteins that are essential, non-essential, or augmenting for growth in vivo.

17. The method of claim 16 , wherein the at least one inactivating mutation is selected from the group consisting of: point mutation, frameshift mutation, truncation mutation, and deletion of all of the nucleic acid sequence encoding the viral protein.

18. The method of claim 16 , wherein the at least one inactivating mutation is in UL82 (pp71).

19. The method of claim 16 , wherein the at least one inactivating mutation is in US11.

20. The method of claim 1 , wherein the first subject is a human or nonhuman primate.

Assignees

• Univ Oregon Health & Science

Inventors

• Frueh Klaus
• Picker Louis
• Hansen Scott
• Sacha Jonah
• Malouli Daniel

Classifications

• A61K40/46

  Viral antigens · CPC title

• A61K40/32

  T-cell receptors [TCR] · CPC title

• A61K40/11

  T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells · CPC title

• A61K35/17

  Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes (when activated by a specific antigen A61K39/00) · CPC title

• C12N5/0636

  T lymphocytes · CPC title